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Human leukocyte antigen-G (HLA-G) is a nonclassical HLA class I antigen that is expressed during pregnancy contributing
to maternal-fetal tolerance. HLA-G can be expressed as membrane-bound and soluble forms. HLA-G expression increases
strongly during viral infections such as congenital human cytomegalovirus (HCMV) infections, with functional consequences in
immunoregulation. In this workwe investigated the expression of soluble (s)HLA-G and beta-2microglobulin (component ofHLA)
molecules in correlation with the risk of transmission and severity of congenital HCMV infection. We analyzed 182 blood samples
from 130 pregnant women and 52 nonpregnant women and 56 amniotic fluid samples from women experiencing primary HCMV
infection. The median levels of sHLA-G in maternal serum of women with primary HCMV infection were higher in comparison
with nonprimary and uninfected pregnant women (𝑝 < 0.001). AF from HCMV symptomatic fetuses presented higher sHLA-G
levels in comparison with infected asymptomatic fetuses (𝑝 < 0.001), presence of HLA-G free-heavy chain, and a concentration
gradient from amniotic fluid to maternal blood. No significant statistical difference of beta-2 microglobulin median levels was
observed between all different groups. Our results suggest the determination of sHLA-G molecules in both maternal blood and
amniotic fluid as a promising biomarker of diagnosis of maternal HCMV primary infection and fetal HCMV disease.
1. Introduction
Human cytomegalovirus (HCMV) is themost common cause
of intrauterine infection, occurring in 0.3% to 2.3% of births
[1]. HCMV intrauterine transmission is more common after
primary infection (30–40% of probability) than after nonpri-
mary infection (1%) [2, 3]. Nevertheless, it was estimated that,
for all population seroprevalences, nonprimary maternal
infections are responsible for themajority of congenital CMV
infections [4].
Ten to fifteen percent of congenitally infected infants of
primarily infected women will have symptoms at birth and
around 10% of them will not survive. Moreover, 70–80% of
surviving babies will suffer delayed sequelae such as sen-
sorineural hearing loss, delay of psychomotor development,
and visual impairment [5]. Most congenital infected infants
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(85–90%) have no symptoms at birth, but 8% to 15% of them
will develop delayed injury [3, 5].
The fetal compartment can be studied by invasive (amnio-
centesis) and noninvasive (ultrasound examination) tech-
niques [6]. Ultrasonographic findings are helpful but not
diagnostic findings since HCMV has features in common
with other intrauterine infections and its sensitivity is poor
[7]. HCMV detection in amniotic fluid with virus isolation
and/or Real-Time PCR is useful for prenatal diagnosis of fetal
infection, due to its high sensitivity and specificity [8–10].
There is still a need for reliable prognostic factors for the
outcome of HCMV fetal infection.
HCMV can modulate the expression and/or function of
human leukocyte antigens (HLA), by encoding proteins to
detain and destroy the expression of HLA molecules on the
surface of infected cells, or selectively upregulate specific
HLA class I molecules binding to immune cell inhibitory
receptors [11]. In this scenario, there is an interesting non-
classical HLA class I antigen, HLA-G, characterized by
low allelic polymorphism, restricted tissue distribution, and
alternative mRNA splicing which creates different isoforms,
4 membrane-bound (HLA-G1–G4) and 3 soluble (HLA-G5–
G7) [12]. In addition, the HLA-G1 isoform can produce a
soluble form called sHLA-G1, derived frommembrane prote-
olytic shedding [13]. HLA-G is expressed at thematernal-fetal
interface, on surface of trophoblasts [12], and the concentra-
tions of soluble (s)HLA-G increase in the plasma samples of
pregnant women during the first trimester of pregnancy [14].
HCMV infection modifies HLA-G expression in tissues and
immune cells, with a downmodulation in infected cytotro-
phoblasts [15] and upregulation in infected peripheral blood
cells [16]. SpecificHCMVproteinsmodifyHLA-G expression
interacting with the HLA-G promoter, and affecting mRNA
stability, protein translation, and the secretory pathway [17–
19].The increase inHLA-G expression is suggested as amech-
anism for virus immune escape, due to the immune-inhibi-
tory functions of HLA-G. Finally, it has been observed that
another important component of HLA class I molecules,
beta-2 microglobulin (b2M), has a diagnostic efficacy for
differentiating symptomatic from asymptomaticHCMVcon-
genital infection [20].
In order to explore the possible role of HLA-G molecules
in congenital HCMV infection, we analyzed maternal and
fetal sHLA-G and b2M expression in correlation with the risk
of transmission and severity of HCMV infection.
2. Materials and Methods
2.1. Subjects. The study analyzed the serum samples of a
cohort of 130 pregnant women who were referred to the
Maternal-Fetal Medicine Unit, St. Orsola-Malpighi Univer-
sity Hospital, Bologna, between 2006 and 2011 for sus-
pected primary maternal HCMV infection. Maternal pri-
mary HCMV infection was assessed at the Virology Unit of
the same University Hospital. Written informed consent for
the studies was obtained from all patients according to the
protocol approved by the Scientific Ethical Committee of the
Ferrara and Bologna Universities.
The women, aged between 18 and 40 years, were in the
first or second trimester of pregnancy. They presented no
previous autoimmune and inflammatory diseases and they
were not on any anti-inflammatory or immune-modulatory
drugs or hyperimmune globulin.
Primary infection was diagnosed based on clinical and
laboratory history and HCMV IgM-positive and low/mod-
erate HCMV IgG avidity results as well as positive DNAemia
and/or seroconversion for HCMV. Nonprimary maternal
HCMV infection was diagnosed, within the first 16 weeks
of gestation, according to blot-confirmed IgM-positivity with
high avidity anti-HCMV IgG and presence of DNA-HCMV
in blood and/or urine and/or saliva.
HCMV-seronegativewomen (for both IgG and IgM)were
defined as uninfected.
Fifty-two nonpregnant women with HCMV past infec-
tion (IgGpositive and IgMnegative) were recruited as healthy
controls.
Moreover, 56 amniotic fluid samples were collected dur-
ing amniocentesis (20-21 weeks of gestation) from those preg-
nant women with primary HCMV infection arising before
the 14th week of gestation; HCMV detection on amniotic
fluid samples was performed with virus isolation and real-
time PCR.
2.2. Diagnosis of Congenital HCMV Infection in Fetuses and
Infants. Infection status of the aborted fetuses was classified
on the basis of histological and immunohistochemical tissue
examination, whereas the infection status of infants was
classified on the basis of viral isolation and real-time PCR
from urine within the first 2 weeks of life.
Fetal symptomatic infection was defined as the presence
of ultrasound abnormalities and histological and immuno-
histochemical findings in fetal organs with particular atten-
tion to the brain [21]. CMV disease in infected newborns was
investigated through clinical, instrumental, and laboratory
examination in the neonatal and subsequently monitored up
to 6 years of age [22].
2.3. Anti-HCMV IgM and IgG Detection and IgG Avidity.
Maternal serum samples were tested using the Enzygnost
HCMV IgM and Enzygnost HCMV IgG assays (Siemens
Healthcare Diagnostics) and an in-house immunoblot for
detection of HCMV-specific IgM [23]. HCMV IgG avidity
was testedwith theRadimCytomegalovirus IgGAvidity EIA
WELL assay (Radim).
2.4. Virological Examinations. HCMV isolation from amni-
otic fluid was performed by shell-vial procedure as described
elsewhere [24]. DNA was extracted from amniotic fluid and
saliva with theNucliSens easyMAGSystem (bioMerieux) and
from blood and urine with the QIAsymphony SP/AS System
(QIAGEN).
HCMV-DNA was quantified with a real-time PCR assay
(HCMV ELITe MGB kit, ELITechGroup) using the ELITe
MGB technology. Amplification, detection, and analysis were
performed with the ABI PRISM 7300 platform (PE Applied
Biosystems). The detection limit was 11 copies/reaction and
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viral load was reported as number of copies/mL for all body
fluids examined.
2.5. Enzyme-Linked Immunosorbent Assay (ELISA) for Soluble
HLA-G. sHLA-G levels in serum and amniotic fluid samples
were assayed in triplicate as previously reported [25, 26]
using the monoclonal antibody (MoAb) MEM-G9 (Exbio),
which recognizes the HLA-G molecules, in b2M associated
form. The intra-assay coefficient of variation (CV) was 1.4%
and the interassay CV was 4.0%. The limit of sensitivity was
1.0 ng/mL.
2.6. ELISA for Soluble Beta-2 Microglobulin and Albumin.
b2M concentration was determined in triplicate using a
commercial humanbeta-2microglobulin ELISAKit (Abcam)
with a detection limit <6 pg/mL.
Albumin concentration was determined in triplicate with
a 1 : 200 dilution using the commercial human albumin
ELISA Kit (Alpha Diagnostic International) with intra-assay
CV of 6.8 to 11.4% and interassay CV of 3.5 to 6.4%.
2.7. Determination of sHLA-G Index. Fetal production of
HLA-G was calculated with the following formula [27]:
sHLA-G Index = amniotic fluid : serum sHLA-G
amniotic fluid : serum albumin
, (1)
where the ratio between amniotic fluid and serum albumin
concentrations represents the status of placental barrier.
2.8. Western Blot Analysis. Serum samples and amniotic
fluids were biotinylatedwith 0.2mg/mLEZ-Link Sulfo-NHS-
LC-Biotin (Pierce) in pH 8.0 PBS 1x for 30min at 4∘C [26].
Samples were then immunoprecipitated for 2 hrs at room
temperature with anti-HLA-G MoAb (MEM-G1, specific for
HLA-G free-heavy chain, or MEM-G9, specific for b2M
conjugatedHLA-G, Exbio), washed twice in PBS 1x, and incu-
bated overnightwith proteinG-Sepharose beads (SantaCruz)
at 4∘C. The samples were washed twice and resuspended in
20𝜇L Laemmli Buffer (BioRad). We quantified protein con-
centration in immunoprecipitates by the Bradford assay (Bio-
Rad Laboratories) using bovine albumin (Sigma-Aldrich) as
standard. Total proteinwas denatured at 100∘C for 5min. Pro-
teinswere loadedwith native or reducing buffers in 10%TGX-
Precast gel (Biorad), with subsequent electroblotting transfer
onto a PVDFmembrane (Millipore) [28].Themembrane was
incubated with a horseradish peroxidase- (HRP-) conjugated
antimouse antibody (1 : 5000; Amersham Biosciences) and
developed with the ECL kit (Amersham Biosciences). The
images were acquired by Geliance 600 (Perkin Elmer).
2.9. Statistics. Statistical analysis was performed with Stat
View software package (SAS Institute Inc). Given that the
data, screened by Kolmogorov-Smirnov test, presented a
normal distribution, statistical analyses were performed
using Student’s 𝑡-test. Frequencies of positive samples for
a specific variable were compared by Fisher exact test. A
logistic regression analysis was performed to evaluate the
effect of different variables. The relationship between sHLA-
G presence and HCMV infection status was investigated by
the Receiver Operating Characteristic (ROC) curve analysis
(JROCFIT software, John Hopkins University).
3. Results
3.1. sHLA-G and Beta-2 Microglobulin Levels in Maternal
Serum Samples. We evaluated sHLA-G and b2M levels in
sera of 130 pregnant women, 30 uninfected, 56 with primary
HCMV infection, and 44 with nonprimary HCMV infection,
and 52 nonpregnant women with HCMV past infection.
Detectable serum levels of sHLA-G were significantly
more frequent in pregnant (130/130; 100%) than in nonpreg-
nant women (31/52; 59.6%) (𝑝 < 0.0001). b2M molecules
presented only slightly higher positive samples in pregnant
women (65/100; 50%) than in nonpregnant women (20/52;
38.5%) (𝑝 = 0.14) (data not shown).
Regarding themedian levels of sHLA-G, pregnantwomen
showed higher levels of molecules in comparison with
nonpregnant women (49 versus 21 ng/mL; range: 37.4–
76.5 ng/mL versus 0.0–20.5 ng/mL) irrespective of HCMV
infection (𝑝 < 0.001) (Figure 1(a)). In addition, we observed
no statistical differences in sHLA-G serum median levels
between actively HCMV infected (56 with primary and
44 with nonprimary infection) and 30 uninfected pregnant
women (47 versus 50 ng/mL; range: 36.2–69.8 versus 37.4–
76.5 ng/mL; 𝑝 = 0.43) (data not shown).
Interestingly, subdividing the subjects according to the
maternal HCMV infection status, primary infected preg-
nant women presented higher levels of sHLA-G median
concentrations (62 ng/mL; 46.9–69.8 ng/mL) than nonpri-
mary infected women (44 ng/mL; 36.2–57.2 ng/mL) (𝑝 <
0.001). Moreover, primary infected pregnant women pre-
sented higher sHLA-G median concentrations than unin-
fected women (50 ng/mL; 37.4–76.5 ng/mL) (𝑝 = 0.006)
(Figure 1(a)).
The median levels of b2M were only slightly higher in
actively HCMV infected (primary and nonprimary) than in
uninfected pregnant women (1.8 versus 1.3 𝜇g/mL; 𝑝 = 0.14),
in primary than in nonprimary HCMV infected (1.9 versus
1.4 𝜇g/mL; 𝑝 = 0.12), and, finally, in primaryHCMV infected
than in uninfected women (1.9 versus 1.3 𝜇g/mL; 𝑝 = 0.06)
(Figure 1(b)).
3.2. sHLA-G and Beta-2 Microglobulin Levels in Amniotic
Fluid. We evaluated sHLA-G and b2M levels in 56 amniotic
fluid samples from women who were primarily HCMV
infected before week 14 of gestation and accepted amniocen-
tesis.
Out of the 56 amniotic fluids, 39 samples were HCMV
negative with PCR and virus isolation and no congenitally
infected newborns were found in this group.
Out of 17 amniotic fluids from mothers who transmitted
the virus to their fetuses/babies, two were negative for both
virus isolation and PCR. Despite these negative results, the 2
babies were congenitally infected, but asymptomatic at birth
and during the follow-up period, as already described in the
literature [9, 10]. The remaining 15 amniotic samples were
positive for both virological tests (6 × 105 copies/mL median
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Figure 1: Maternal serum samples expression of (a) sHLA-G and (b) b2Mmolecules in nonpregnant and pregnant women. Pregnant women
are classified as uninfected and primarily and nonprimarily HCMV infected. 𝑝 values obtained by Student’s 𝑡-test and mean ± standard
deviation are reported.
viral load) except for one case where only HCMV-DNA was
detected (103 copies/mL).
Overall, out of the 17 fetuses/babies infected with con-
genital HCMV, 5 newborns were asymptomatic at birth and
during subsequent monitoring and 11 fetuses and 1 newborn
were symptomatic.
The brains of all symptomatic fetuses were HCMV
positive with severe histological brain damage and cerebral
necrosis; 4 of the fetuses also showed pathological neu-
rosonographic findings (periventricular hyperechogenicity
and ventriculomegaly).
Moreover, the only symptomatic newborn had hepatosple-
nomegaly, thrombocytopenia (platelet count: <100.000/mm3),
and alanine aminotransferase elevation (>80U/L) at birth
and developed sequelae with sensorineural hearing loss and
mild psychomotor retardation.
No statically significant difference in amniotic fluid
HCMV load was observed between asymptomatic and symp-
tomatic fetuses/newborns (𝑝 = 0.88, 95% CI: −3583021 to
3110188).
All the 56 amniotic fluid samples were positive for sHLA-
G and b2Mmolecules (data not shown).
Median detectable levels of sHLA-G were significantly
higher in amniotic fluids from infected symptomatic fetuses
(73 ng/mL; 69–79 ng/mL) than in infected asymptomatic
fetuses (32 ng/mL; 28–42 ng/mL) (𝑝 < 0.001) and in
uninfected fetuses (31 ng/mL; 29–40.2 ng/mL) (𝑝 < 0.001)
(Figure 2(a)).
b2M presented slightly higher median levels in amniotic
fluids from infected symptomatic fetuses (4.5𝜇g/mL) than in
infected asymptomatic fetuses (3.6𝜇g/mL) (𝑝 = 0.039) and
uninfected fetuses (3.9 𝜇g/mL) (𝑝 = 0.042) (Figure 2(b)).
When we considered maternal serum levels according to
fetus infection status, we observed that sHLA-G concentra-
tions were slightly higher in serum from women with symp-
tomatic fetuses (51.2 ng/mL, 45–57 ng/mL) and in women
with infected asymptomatic fetuses (49 ng/mL, 42–55 ng/mL)
in comparison with uninfected fetuses (46 ng/mL, 44–
52 ng/mL) (𝑝 = 0.045, 𝑝 = 0.042, resp.) (Figure 2(c)).
b2M presented no differences in serum samples from
women with infected symptomatic fetuses, infected asymp-
tomatic fetuses, and uninfected fetuses (Figure 2(d)).
3.3. sHLA-GConcentrationGradient betweenMaternal Serum
and Amniotic Fluid. The sHLA-G increase in amniotic fluids
of infected symptomatic fetuses prompted the question of
whether sHLA-G was produced locally in amniotic com-
partment or derived from maternal blood. Fetal and mater-
nal compartments are mutually interconnected and several
molecules are exchanged through the amniotic and chorionic
membrane. This molecular interchange could be hypothe-
sized also for HLA molecules. Therefore we evaluated the
concentration gradient between serum samples fromprimary
infected women and the corresponding amniotic fluids.
A sHLA-G concentration gradient from the amniotic
fluid to the maternal serum was observed only in infected
symptomatic fetuses, while uninfected and infected asymp-
tomatic fetuses presented an inverse sHLA-G gradient (Fig-
ure 3(a)). These results suggest a local fetal production of
sHLA-G, increased only in fetuses with symptomatic HCMV
infection.
3.4. sHLA-G Index. The association between fetal HCMV
infection and increased sHLA-G expression in amniotic fluid
was confirmed calculating the sHLA-G index in comparison
with albumin. Albumin is the most prevalent serum protein
which surrounds the embryo and is detected in amniotic
fluids. Fainardi et al. [27] reported the use of cerebrospinal
fluid and serum albumin content to evaluate sHLA-G brain
production. Since both blood-brain interface andplacenta are
considered selective barriers, we applied the same concept
to quantify the fetal compartment production of sHLA-G,
Journal of Immunology Research 5
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Figure 2: Amniotic fluid samples expression of (a) sHLA-G and (b) b2Mmolecules according to the fetal/neonatal outcome.Maternal serum
samples expression of (c) sHLA-G and (d) b2Mmolecules according to the fetal/neonatal outcome. 𝑝 values obtained by Student’s 𝑡-test and
mean ± standard deviation are reported.
evaluating the relative amount of amniotic sHLA-G and
albumin compared with maternal serum levels. Any increase
in the index could be ascribed to sHLA-G production in
the fetal compartment. The highest sHLA-G indexes were
detected in infected symptomatic fetuses (19.5%) compared
to infected asymptomatic fetuses (6%) and uninfected (5.1%)
(𝑝 < 0.001, 𝑝 < 0.001, resp.) (Figure 3(b)).
3.5. HLA-G Free-Heavy Chain Analysis. HLA-G can be
expressed as b2M associated or free-heavy chain. Previous
studies documented a different distribution of these two con-
formations at the maternal-fetus interface [29]. We evaluated
the presence of HLA-G free-heavy chain in both sera and
in amniotic fluids from primary HCMV infected pregnant
women with asymptomatic or symptomatic fetus. HLA-G
free-heavy chain was detected with a tendency to be more
frequent in amniotic fluids from symptomatic fetuses (𝑝 =
0.074). On the contrary, maternal sera did not present HLA-
G free-heavy chain (Table 1).
Representative examples of maternal serum and AF reac-
tivity to antigens on theWestern blot are shown in Figure 3(c).
In lines 1, 2, and 3, we reported HLA-G positive samples
analyzed for b2M associated form (MEM-G9 detection),
while the same samples were analyzed for HLA-G free-heavy
chain (MEM-G1 detection) in lines 4, 5, and 6.
3.6. sHLA-G Predictive Efficacy. We analyzed serum and
amniotic fluid samples for sHLA-G and selected different cut-
offs to be used as differentiation values. ROC analysis showed
serum values above 50 ng/mL and amniotic values above
30 ng/mL with the highest sensitivity and specificity and an
Area Under an ROC Curve of 0.83 and 0.86, respectively
6 Journal of Immunology Research
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Figure 3: (a) sHLA-G concentration gradients according to the fetal/neonatal outcome. (b) sHLA-G indexes (%) according to the
fetal/neonatal outcome. (c) Representative Western blot analysis of maternal serum and amniotic fluids samples from HCMV primary
infected pregnancy subdivided according to the fetal/neonatal outcome. The analysis were performed after immunoprecipitation with anti-
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supernatants were used as positive control (M) and the positivity for HLA-G molecule was evidenced at 39 kD.
Table 1: Prognostic HLA-G biomarker of symptomatic congenital HCMV infection.
Parameters Cutoff
Fetuses Diagnostic accuracy
AUA95% CI
Sympt Asympt Sens% Spec% PPV% NPV%
Maternal serum samples
HLA-G free-heavy chain Presence 0 0 0 100 0 29.4 0.5
Absence 12 5 0–26.7 47.9–100 10.4–55.9
sHLA-G 50 ng/mL Above 10 0 83.3 100 100 71.4 0.83
Below 2 5 51.6–97.4 47.9–100 68.9–100 29.3–95.5
Amniotic fluid samples
HLA-G free-heavy chain Presence 12 3 100 40 80 100 0.79
Absence 0 2 73.3–100 6.4–84.6 51.9–95.4 19.2–100
sHLA-G 30 ng/mL Above 11 0 91.7 100 100 83.3 0.86
Below 1 5 61.5–98.6 47.9–100 71.3–100 36.1–97.2
Sens: sensitivity; Spec: specificity; PPV: positive predictive value; NPV: negative predictive value; AUA: Area Under an ROC Curve; Sympt: symptomatic;
Asympt: asymptomatic.
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(Table 1), in differentiating symptomatic from asymptomatic
congenital infections. Similarly, the presence of HLA-G free-
heavy chain in amniotic fluids shows a high sensitivity and
specificity and an Area Under an ROCCurve of 0.79, in iden-
tifying symptomatic congenital infections. Logistic regres-
sion analysis excluded the presence of confounding variables.
4. Discussion
The prenatal diagnosis provides the optimal means for diag-
nosingHCMV fetal infection.The specificity is very good and
the sensitivity depends on the kind of samples used (amniotic
fluid > fetal blood), the technique used (Real-Time PCR-
Polymerase Chain Reaction> viral culture), and the timing of
the procedure with respect to the onset of maternal infection
and the gestational age.
All literature data report that the amniotic fluid is the
most appropriate material for the diagnosis of fetal HCMV
infection. Positive results in amniotic fluid identify all HCMV
infected fetuses (positive predictive value = 100%) but do not
identify the infants who will have symptoms at birth [6].
Although the highest median values of HCMV-DNA
in amniotic fluid tend to indicate an increased risk of
severe infection, high viral loads may be associated with
symptomatic or asymptomatic congenital infections. Indeed,
a correlation between the high HCMV load in amniotic fluid
and fetal/neonatal outcome has not been demonstrated [6].
More recently, some studies have evoked the prognostic
value of fetal viremia/viral load and/or level of specific IgM;
however this remains controversial. It has been proposed
that platelet count gives a better indication. New data has
demonstrated that the determination of multiple markers
(haematological, biochemical, and virological markers) in
fetal blood following virus detection in amniotic fluid is
predictive of perinatal outcome in fetuses with HCMV infec-
tion [21]. Further studies in a larger number of symptomatic
cases should be performed to verify the prognostic efficacy of
determination of multiple parameters in fetal blood.
In this work, we analyzed the levels of sHLA-G and b2M
molecules in the maternal serum samples and showed that
sHLA-G median levels were significantly higher in maternal
serum from pregnant women with primary HCMV infection
than in nonprimary and uninfected, respectively (𝑝 < 0.001
and 𝑝 < 0.006). On the contrary, beta-2 microglobulin levels
were only slightly higher in maternal serum from pregnant
women with primary HCMV infection than in nonprimary
and uninfected, respectively (𝑝 = 0.12 and 𝑝 = 0.06).
The differences in immune competence towards HCMV in
primary infected and in nonprimary infected mothers could
explain the different production of sHLA-G that can act as
viral immune escape mechanism or as a tentative reduction
of immune activation in primary HCMV infection, which is
not induced in nonprimary HCMV infected women.
Furthermore, we evaluated whether sHLA-G molecules
could be considered prognostic biomarkers of symptomatic
congenital HCMV infection.
We observed that sHLA-G levels in both maternal
serum and amniotic fluid samples are significantly related to
symptomatic HCMV fetal infections as supported by ROC
analysis (Table 1). In fact, sHLA-G levels above 50 ng/mL in
maternal blood and 30 ng/mL in amniotic fluid are correlated
with symptomatic HCMV congenital infections. High levels
of sHLA-G in maternal and fetal compartments show a
specificity of 100% for symptomatic congenital infection and
a sensitivity ranging between 83 and 92%.
The evidence that sHLA-G levels increase only in the
presence of symptomatic fetuses suggests a specific fetal
production of these molecules. We obtained confirmation
of this hypothesis through (i) the evaluation of the con-
centration gradient, which is higher in the amniotic fluid
versus the maternal blood in case of symptomatic infection;
(ii) the sHLA-G indexes calculation, which support a fetal
production; (iii) the HLA-G free-heavy chian, which is
commonly expressed by distal trophoblasts [29], which is
present only in amniotic fluid.
The increase of fetal HLA-G expression could be caused
by HCMV-encoded proteins that are known to interact with
HLA mRNAs and proteins, modifying their stability and
secretory pathways [15–19]. The increase of HLA-G expres-
sion could enhance HCMV immune escape, increasing the
risk of congenital infections and symptomatic sequelae. Our
results suggest that serum and amniotic fluid sHLA-G might
be an additional biomarker of congenital HCMV infection
that could be considered in combination with currently used
viral and biological markers [20, 30], providing the best key
to the reliable identification of fetuses at risk of congenital
disease as well as of fetuses with a favorable outcome.
5. Conclusions
To the best of our knowledge, this is the first observation that
considers the possible use of serum and amniotic fluid sHLA-
G as a biomarker to discriminate between symptomatic and
asymptomatic HCMV congenital infection. However, future
studies with larger cohort of fetuses should be performed
in order to verify whether the addition of serum sHLA-
G determination to virologic markers may be crucial in
identifying fetuses at highest risk of severe pathologies.
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